Literature DB >> 18478328

Myelin lipid abnormalities in the aspartoacylase-deficient tremor rat.

Jianfeng Wang1, Paola Leone, Gusheng Wu, Jeremy S Francis, Hong Li, Mohit Raja Jain, Tadao Serikawa, Robert W Ledeen.   

Abstract

The high concentration of N-acetylaspartate (NAA) in neurons of the central nervous system and its growing clinical use as an indicator of neuronal viability has intensified interest in the biological function of this amino acid derivative. The biomedical relevance of such inquiries is highlighted by the myelin-associated pathology of Canavan disease, an inherited childhood disorder resulting from mutation of aspartoacylase (ASPA), the NAA-hydrolyzing enzyme. This enzyme is known to be localized in oligodendrocytes with bimodal distribution in cytosol and the myelin sheath, and to produce acetyl groups utilized in myelin lipid synthesis. Loss of this acetyl source in Canavan disease and rodent models such as the tremor rat are thought to account for the observed myelin deficit. This study was undertaken to further define and quantify the specific lipid abnormalities that occur as a result of ASPA deficit in the tremor rat. Employing mass spectrometry together with high performance thin-layer chromatography, we found that myelin from 28-day-old animals showed major reduction in cerebrosides (CB) and sulfatides (Sulf) with unsubstituted fatty acids, and equal if not greater changes in myelin from 7-month-old tremors. Cerebrosides with 2-hydroxyfatty acids showed little if any change at either age; Sulf with 2-hydroxyfatty acids showed no significant change at 28 days, but surprisingly a major increase at 7 months. Two species of phosphatidylcholine, 32:0 and 34:1, also showed significant increase, but only at 28 days. One form of phosphatidylethanolamine, PE36:1, was reduced a modest amount at both ages, whereas the plasmalogen form did not change. The dysmyelination that results from inactivation of ASPA is thus characterized by selective decreases as well as some increases in specific lipids.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18478328      PMCID: PMC4640699          DOI: 10.1007/s11064-008-9726-5

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  32 in total

Review 1.  Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia.

Authors:  A A Farooqui; L A Horrocks
Journal:  Neuroscientist       Date:  2001-06       Impact factor: 7.519

2.  A myelin galactolipid, sulfatide, is essential for maintenance of ion channels on myelinated axon but not essential for initial cluster formation.

Authors:  Tomoko Ishibashi; Jeffrey L Dupree; Kazuhiro Ikenaka; Yukie Hirahara; Koichi Honke; Elior Peles; Brian Popko; Kinuko Suzuki; Hitoo Nishino; Hiroko Baba
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

Review 3.  Physiological role of N-acetylaspartate: contribution to myelinogenesis.

Authors:  Robert W Ledeen; Jianfeng Wang; Gusheng Wu; Zi-Hua Lu; Goutam Chakraborty; Markus Meyenhofer; Stephen K Tyring; Reuben Matalon
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

4.  Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI.

Authors:  C G Janson; S W J McPhee; J Francis; D Shera; M Assadi; A Freese; P Hurh; J Haselgrove; D J Wang; L Bilaniuk; P Leone
Journal:  Neuropediatrics       Date:  2006-08       Impact factor: 1.947

5.  Accumulation of N-acetyl-L-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system.

Authors:  K Kitada; T Akimitsu; Y Shigematsu; A Kondo; T Maihara; N Yokoi; T Kuramoto; M Sasa; T Serikawa
Journal:  J Neurochem       Date:  2000-06       Impact factor: 5.372

Review 6.  Galactolipids are molecular determinants of myelin development and axo-glial organization.

Authors:  Jill Marcus; Brian Popko
Journal:  Biochim Biophys Acta       Date:  2002-12-19

7.  Fatty acid synthesizing enzymes intrinsic to myelin.

Authors:  Goutam Chakraborty; Robert Ledeen
Journal:  Brain Res Mol Brain Res       Date:  2003-04-10

8.  Modification of the Lowry procedure for the analysis of proteolipid protein.

Authors:  M B Lees; S Paxman
Journal:  Anal Biochem       Date:  1972-05       Impact factor: 3.365

Review 9.  Gangliosides: structure, isolation, and analysis.

Authors:  R W Ledeen; R K Yu
Journal:  Methods Enzymol       Date:  1982       Impact factor: 1.600

10.  Fatty acid and fatty aldehyde composition of the major brain lipids in normal human gray matter, white matter, and myelin.

Authors:  J S O'Brien; E L Sampson
Journal:  J Lipid Res       Date:  1965-10       Impact factor: 5.922

View more
  20 in total

1.  A combined diffusion tensor imaging and magnetic resonance spectroscopy study of patients with schizophrenia.

Authors:  Meredith A Reid; David M White; Nina V Kraguljac; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2015-12-21       Impact factor: 4.939

Review 2.  Clinical applications involving CNS gene transfer.

Authors:  Boris Kantor; Thomas McCown; Paola Leone; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

3.  Aspartoacylase supports oxidative energy metabolism during myelination.

Authors:  Jeremy S Francis; Louise Strande; Vladamir Markov; Paola Leone
Journal:  J Cereb Blood Flow Metab       Date:  2012-05-23       Impact factor: 6.200

4.  Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease.

Authors:  Peethambaran Arun; Chikkathur N Madhavarao; John R Moffett; Kristen Hamilton; Neil E Grunberg; Prasanth S Ariyannur; William A Gahl; Yair Anikster; Steven Mog; William C Hallows; John M Denu; Aryan M A Namboodiri
Journal:  J Inherit Metab Dis       Date:  2010-05-13       Impact factor: 4.982

5.  Extensive aspartoacylase expression in the rat central nervous system.

Authors:  John R Moffett; Peethambaran Arun; Prasanth S Ariyannur; James Y Garbern; David M Jacobowitz; Aryan M A Namboodiri
Journal:  Glia       Date:  2011-05-19       Impact factor: 7.452

6.  Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease.

Authors:  Jeremy S Francis; Vladimir Markov; Paola Leone
Journal:  J Inherit Metab Dis       Date:  2013-11-28       Impact factor: 4.982

7.  Long-term follow-up after gene therapy for canavan disease.

Authors:  Paola Leone; David Shera; Scott W J McPhee; Jeremy S Francis; Edwin H Kolodny; Larissa T Bilaniuk; Dah-Jyuu Wang; Mitra Assadi; Olga Goldfarb; H Warren Goldman; Andrew Freese; Deborah Young; Matthew J During; R Jude Samulski; Christopher G Janson
Journal:  Sci Transl Med       Date:  2012-12-19       Impact factor: 17.956

8.  Central myelin gene expression during postnatal development in rats exposed to nicotine gestationally.

Authors:  Junran Cao; Jennifer B Dwyer; Nicole M Gautier; Frances M Leslie; Ming D Li
Journal:  Neurosci Lett       Date:  2013-08-17       Impact factor: 3.046

9.  A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice.

Authors:  Seemin Seher Ahmed; Huapeng Li; Chunyan Cao; Elif M Sikoglu; Andrew R Denninger; Qin Su; Samuel Eaton; Ana A Liso Navarro; Jun Xie; Sylvia Szucs; Hongwei Zhang; Constance Moore; Daniel A Kirschner; Thomas N Seyfried; Terence R Flotte; Reuben Matalon; Guangping Gao
Journal:  Mol Ther       Date:  2013-07-02       Impact factor: 11.454

10.  Glyceryl triacetate for Canavan disease: a low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model.

Authors:  C N Madhavarao; P Arun; Y Anikster; S R Mog; O Staretz-Chacham; J R Moffett; N E Grunberg; W A Gahl; A M A Namboodiri
Journal:  J Inherit Metab Dis       Date:  2009-08-15       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.